| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
To examine whether NK cells are involved in cetuximab’s antitumor effect, we removed NK cells from mice using anti‐asialo GM1 antibody (antibody that recognizes the glycolipid asialo GM1 expressed on the cell membrane of NK cells) and investigated the results. Although cetuximab tended to have a weaker effect in the group without NK cells, there was no clear significant difference. We investigated the correlation between cetuximab and ADCC activity using an ADCC measurement kit, but we were unable to detect cetuximab-induced ADCC activity in the cell lines we used. We think that perhaps the cancer cells we used had low levels of EGFR expression, which meant we were unable to detect sufficient levels of ADCC activity. Based on the above information, we feel it is essential to use cancer cells with high levels of EGFR expression for future research on ADCC activity.
|
